BlackThorn ACQUIRED: NEUMORA | PUBLIC Discovery and development of novel, targeted treatments for neurobehavioral disorders http://www.blackthornrx.com Press Releases BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders Jan 23, 2020 BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders Dec 11, 2019 BlackThorn Therapeutics Reports New Insights into Neurobehavioral Disorders Oct 23, 2019 BlackThorn Therapeutics Appoints William J. Martin, Ph.D., as CEO to Lead New Stage Growth Oct 21, 2019 BlackThorn Therapeutics Appoints Healthcare Technology Innovator, Monique Levy, as Chief Strategy Officer Sep 9, 2019 BlackThorn Therapeutics Closes $76 Million Series B to Advance Targeted Therapeutics for Mental Health Jun 13, 2019 BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140 Apr 1, 2019 BlackThorn Therapeutics Announces R&D Updates Jan 4, 2019 BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer Nov 5, 2018 BlackThorn Therapeutics Announces Participation in Key Data Science and Cloud Computing Panels to Advance Therapeutic Development at 2018 BIO Investor Forum Oct 11, 2018 Press Coverage Neuroscience is Taking the Spotlight at Xconomy’s Bay Area Xchange Nov 11, 2019 TechCrunch: Neurobehavioral health company BlackThorn pulls in $76 million from GV to treat mental disorders Jun 17, 2019 Yale News: Marriage of imaging and genetics opens new view of brain function Aug 16, 2018 BlackThorn Therapeutics Initiates Phase 1 Study of BTRX-335140, an Investigational Kappa Opioid Receptor (KOR) Antagonist Jun 6, 2018 FierceBiotech: Pivotal moments for this year’s Fierce 15 winners Sep 28, 2017 FierceBiotech: FierceBiotech’s 2017 Fierce 15 Sep 26, 2017 BioCentury: Circuit logic—how blackthorn is taking an algorithmic approach to neurological drug development Jul 28, 2017
BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders Jan 23, 2020
BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders Dec 11, 2019
BlackThorn Therapeutics Appoints William J. Martin, Ph.D., as CEO to Lead New Stage Growth Oct 21, 2019
BlackThorn Therapeutics Appoints Healthcare Technology Innovator, Monique Levy, as Chief Strategy Officer Sep 9, 2019
BlackThorn Therapeutics Closes $76 Million Series B to Advance Targeted Therapeutics for Mental Health Jun 13, 2019
BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140 Apr 1, 2019
BlackThorn Therapeutics Announces Participation in Key Data Science and Cloud Computing Panels to Advance Therapeutic Development at 2018 BIO Investor Forum Oct 11, 2018
TechCrunch: Neurobehavioral health company BlackThorn pulls in $76 million from GV to treat mental disorders Jun 17, 2019
BlackThorn Therapeutics Initiates Phase 1 Study of BTRX-335140, an Investigational Kappa Opioid Receptor (KOR) Antagonist Jun 6, 2018
BioCentury: Circuit logic—how blackthorn is taking an algorithmic approach to neurological drug development Jul 28, 2017
